{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:53:19Z","timestamp":1793245999912,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaci.2023.07.010","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T11:23:08Z","timestamp":1690888988000},"page":"1394-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["The role of Janus kinase signaling in the pathology of atopic dermatitis"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.07.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaci.2023.07.010_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1203475420911896","article-title":"Adult-onset atopic dermatitis: presentations and progress","volume":"24","author":"Chan","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.07.010_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039803","article-title":"Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies","volume":"7","author":"Deckers","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.07.010_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jdv.15574","article-title":"Distribution of atopic dermatitis lesions in United States adults","volume":"33","author":"Silverberg","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.07.010_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaip.2017.10.005","article-title":"Phenotypical differences of childhood- and adult-onset atopic dermatitis","volume":"6","author":"Silverberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.07.010_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaci.2016.08.029","article-title":"Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling","volume":"139","author":"Ewald","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib7","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.02.001","article-title":"New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity","volume":"70","author":"Kabashima","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.07.010_bib10","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jaci.2020.02.008","article-title":"Reconciling innate and acquired immunity in atopic dermatitis","volume":"145","author":"Honda","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaci.2021.10.022","article-title":"Advances in atopic dermatitis in 2019-2020: Endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells","volume":"148","author":"Nomura","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib12","doi-asserted-by":"crossref","unstructured":"Facheris P, Da Rosa JC, Pagan AD, Angelov M, Del Duca E, Rabinowitz G, et\u00a0al. Age of onset defines two distinct profiles of atopic dermatitis in adults. Allergy 2023;78:2202-14.","DOI":"10.1111\/all.15741"},{"key":"10.1016\/j.jaci.2023.07.010_bib13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"10.1016\/j.jaci.2023.07.010_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"10.1016\/j.jaci.2023.07.010_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155664","article-title":"Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans","volume":"148","author":"Nakajima","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2023.07.010_bib16","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib18","unstructured":"Cameron MJ, Kelvin DJ. Cytokines, chemokines and their receptors. In: Madame Curie bioscience database. Landes Bioscience. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6294\/. Accessed June 10, 2022."},{"key":"10.1016\/j.jaci.2023.07.010_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and\u00a0emerging systemic treatments for atopic dermatitis","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2023.07.010_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/ALX02272E","article-title":"Janus kinase inhibitors for the therapy of atopic dermatitis","volume":"5","author":"Traidl","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.jaci.2023.07.010_bib21","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2741\/4054","article-title":"IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?","volume":"17","author":"Camporeale","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.jaci.2023.07.010_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jaci.2023.07.010_bib23","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jaci.2023.07.010_bib24","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.07.010_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2023.07.010_bib26","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1172\/JCI82887","article-title":"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.07.010_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100329","article-title":"Dysregulated ceramide metabolism in mouse progressive dermatitis resulting from constitutive activation of Jak1","volume":"64","author":"Iino","year":"2023","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaci.2023.07.010_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clindermatol.2011.08.023","article-title":"Abnormal epidermal barrier in the pathogenesis of atopic dermatitis","volume":"30","author":"Wolf","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib30","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.07.010_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/cea.12495","article-title":"Pathogenesis of atopic dermatitis","volume":"45","author":"Peng","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.07.010_bib33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib34","first-page":"295","article-title":"The relationship between outdoor air pollutants and atopic dermatitis of adults: a systematic review and meta-analysis","volume":"40","author":"Hsiao","year":"2022","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/jid.2010.277","article-title":"IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction?","volume":"131","author":"Hvid","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib36","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib37","first-page":"13","article-title":"The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment","volume":"31","author":"Alsabbagh","year":"2022","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jaci.2023.07.010_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/362245a0","article-title":"Disruption of the murine IL-4 gene blocks Th2 cytokine responses","volume":"362","author":"Kopf","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.07.010_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/jid.2010.382","article-title":"The Th2 systemic immune milieu enhances cutaneous inflammation in the K14-IL-4-transgenic atopic dermatitis model","volume":"131","author":"Reichle","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib40","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.4049\/jimmunol.180.5.3551","article-title":"IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6","volume":"180","author":"Sehra","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib41","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.4049\/jimmunol.168.4.2020","article-title":"Development of atopic dermatitis-like skin lesions in STAT6-deficient NC\/Nga mice","volume":"168","author":"Yagi","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib42","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/jid.2013.503","article-title":"In\u00a0vitro assessment of IL-4- or IL-13-mediated changes in the structural components\u00a0of keratinocytes in mice and humans","volume":"134","author":"Omori-Miyake","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cyto.2012.10.031","article-title":"IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in\u00a0vivo and in\u00a0vitro: relevant in the pathogenesis of atopic dermatitis","volume":"61","author":"Bao","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2023.07.010_bib44","first-page":"1061","article-title":"Biological therapies for atopic dermatitis: an update","volume":"17","author":"Deleanu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jaci.2023.07.010_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100042","article-title":"A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis","volume":"1","author":"Kamata","year":"2021","journal-title":"JID Innov"},{"key":"10.1016\/j.jaci.2023.07.010_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2017.05.007","article-title":"IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies","volume":"45","author":"Passalacqua","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2023.07.010_bib47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.jid.5700085","article-title":"IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: possible role in atopic dermatitis","volume":"126","author":"Purwar","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41590-021-01067-0","article-title":"Homeostatic IL-13 in healthy skin directs dendritic cell differentiation to promote T(H)2 and inhibit T(H)17 cell polarization","volume":"22","author":"Mayer","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.07.010_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/intimm\/dxq027","article-title":"Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis","volume":"22","author":"Cheung","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib51","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/s41598-018-25094-4","article-title":"IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity","volume":"8","author":"Takamori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.07.010_bib52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib53","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2133.2012.11047.x","article-title":"Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3\/calcium axis in atopic dermatitis","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib54","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib55","doi-asserted-by":"crossref","first-page":"33676","DOI":"10.1074\/jbc.M204204200","article-title":"Interleukin-22 (IL-22) activates the JAK\/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10","volume":"277","author":"Lejeune","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.07.010_bib56","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.4049\/jimmunol.1600126","article-title":"Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway","volume":"198","author":"Lou","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib58","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1172\/JCI5669","article-title":"Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis","volume":"103","author":"Spergel","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.07.010_bib60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.07.010_bib61","doi-asserted-by":"crossref","first-page":"41679","DOI":"10.1074\/jbc.M406413200","article-title":"Alternative activation of STAT1 and STAT3 in response to interferon-gamma","volume":"279","author":"Qing","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.07.010_bib62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.07.010_bib63","first-page":"WC01","article-title":"Immunoglobulin e, interleukin-18 and interleukin-12 in patients with atopic\u00a0dermatitis: correlation with disease activity","volume":"9","author":"Zedan","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jaci.2023.07.010_bib64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/039463200802100213","article-title":"Total IL-12 levels are increased in paediatric atopic dermatitis: correlations with age and disease severity","volume":"21","author":"Piancatelli","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaci.2023.07.010_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058196","article-title":"IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice","volume":"8","author":"Bromley","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.07.010_bib66","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1091\/mbc.E14-12-1645","article-title":"Defining the functional binding sites of interleukin 12 receptor beta1 and interleukin 23 receptor to Janus kinases","volume":"27","author":"Floss","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jaci.2023.07.010_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2023.07.010_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups\u2013variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib70","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","article-title":"Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis","volume":"181","author":"Guttman-Yassky","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18176\/jiaci.0699","article-title":"Circulating epithelial cell cytokines are associated with early-onset atopic dermatitis","volume":"32","author":"Gamez","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12026-012-8264-z","article-title":"Functions of thymic stromal lymphopoietin in immunity and disease","volume":"52","author":"Zhang","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaci.2023.07.010_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal\u00a0transduction by the atopy-associated human thymic stromal lymphopoietin\u00a0(TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.jaci.2023.07.010_bib75","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.4049\/jimmunol.1402760","article-title":"A novel IL-25 signaling pathway through STAT5","volume":"194","author":"Wu","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.08.006","article-title":"Interleukin-33 in atopic dermatitis","volume":"96","author":"Imai","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.07.010_bib77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5114\/ada.2021.105412","article-title":"Combination of FLG mutations and SNPs of IL-17A and IL-19 influence on atopic dermatitis occurrence","volume":"39","author":"Klonowska","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2023.07.010_bib78","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay","volume":"9","author":"Konrad","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.07.010_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.07.010_bib80","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2340\/00015555-2723","article-title":"Increased interleukin-19 expression in cutaneous T-cell lymphoma and atopic dermatitis","volume":"97","author":"Oka","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.07.010_bib81","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11882-008-0049-z","article-title":"What causes itch in atopic dermatitis?","volume":"8","author":"Yosipovitch","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2023.07.010_bib82","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2020.06.023","article-title":"The cytokine TGF-beta induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching","volume":"53","author":"Xu","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.07.010_bib84","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1398-9995.2011.02545.x","article-title":"Functional effects of interleukin 31 in human primary keratinocytes","volume":"66","author":"Kasraie","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.07.010_bib85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.07.010_bib86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.07.010_bib87","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.07.010_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2023.07.010_bib89","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaci.2010.08.041","article-title":"Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression","volume":"126","author":"Oyoshi","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-015-0759-2","article-title":"Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1beta production","volume":"17","author":"Pinto","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2023.07.010_bib91","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030229","article-title":"Intractable itch in atopic dermatitis: causes and treatments","volume":"9","author":"Umehara","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2023.07.010_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4419-8056-4_8","article-title":"Histamine and antihistamines in atopic dermatitis","volume":"709","author":"Buddenkotte","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaci.2023.07.010_bib94","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaad.2021.04.021","article-title":"A real-world study of the longitudinal course of skin pain in adult atopic dermatitis","volume":"86","author":"Hong","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib95","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8564215","article-title":"Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets--a focus on the JAK-STAT pathway","volume":"2018","author":"Salaffi","year":"2018","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.jaci.2023.07.010_bib96","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.07.010_bib97","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2023.07.010_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916644927","article-title":"Interferon-gamma potentiates NMDA receptor signaling in spinal dorsal horn neurons via microglia-neuron interaction","volume":"12","author":"Sonekatsu","year":"2016","journal-title":"Mol Pain"},{"key":"10.1016\/j.jaci.2023.07.010_bib99","doi-asserted-by":"crossref","first-page":"14415","DOI":"10.1523\/JNEUROSCI.4569-09.2009","article-title":"T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity","volume":"29","author":"Costigan","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.jaci.2023.07.010_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2606808","article-title":"The elevated serum level of IFN-gamma in patients with failed back surgery syndrome remains unchanged after spinal cord stimulation","volume":"2019","author":"Kamieniak","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.jaci.2023.07.010_bib101","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1073\/pnas.0810420106","article-title":"IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain","volume":"106","author":"Tsuda","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.07.010_bib102","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib103","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.anai.2023.03.010","article-title":"Atopic dermatitis yardstick update","volume":"130","author":"Boguniewicz","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib104","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2023.07.010_bib105","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaci.2023.07.010_bib106","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib107","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.07.010_bib108","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib109","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib110","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.07.010_bib111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.07.010_bib112","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.jaip.2022.08.042","article-title":"Magnitude and time course of response to abrocitinib for moderate-to-severe atopic dermatitis","volume":"10","author":"Reich","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.07.010_bib113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/12034754221088542","article-title":"Rapid improvement in skin pain severity and its impact on quality of life in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study","volume":"26","author":"Rosmarin","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.07.010_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2023.07.010_bib115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib117","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy\u00a0and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.07.010_bib118","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"5","author":"Bantz","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2021.04.010","article-title":"Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma","volume":"149","author":"Badi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.07.010_bib120","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/cea.14189","article-title":"Early-onset atopic dermatitis and food hypersensitivity increase the risk of atopic march","volume":"52","author":"Pesonen","year":"2022","journal-title":"Clin Exp Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923009703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923009703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:44:30Z","timestamp":1758793470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923009703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0091674923009703"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.07.010","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of Janus kinase signaling in the pathology of atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}